NASDAQ · Biotechnology
FBIO (FBIO) Stock
$2.67
-3.61%
NASDAQ: FBIO
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Journey Medical (DERM) Stock Draws Fresh Price Target Split After Fortress Valuation Changes
Simply Wall St. · Jun 25, 2026
Journey Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference
GlobeNewswire · May 19, 2026
Fortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference
GlobeNewswire · May 18, 2026
Fortress Biotech: Q1 Earnings Snapshot
Associated Press · May 14, 2026
Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
GlobeNewswire · May 14, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held22.79%
Institutions Held24.76%
Institutions Float Held32.07%
Peer Comparison
About FBIO
FBIO is led by CEO Lindsay Allan Rosenwald, employs 101 people, headquartered in US, publicly traded since 2011.
FBIO stock trades at $2.67 with a market capitalization of $88.69M. The stock is valued at a price-to-earnings (P/E) ratio of 0.91, price-to-book of 0.60, price-to-sales of 1.48. Over the past 52 weeks the stock has ranged between $1.70 and $4.53, and currently trades 41.1% below its 52-week high.
On profitability, FBIO generates a return on equity (ROE) of 109.80% — well above the market average, a sign of a high-quality business, return on capital employed of -111.11%, an operating margin of -84.36%, a net profit margin of 1.93%.